AstraZeneca Exanta Risk Plan Not Sufficient To Allay Liver Toxicity Concerns

AstraZeneca's proposed Exanta risk management plan is not sufficient to alleviate liver toxicity concerns with the anticoagulant, FDA's Cardiovascular & Renal Drugs Advisory Committee said